Galapagos

🇧🇪Belgium

Country: 🇧🇪Belgium

Ownership: Public

Established: 1999-01-01

Employees: 1.1K

Market Cap: $1.9B

Website: http://www.glpg.com

Introduction: Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. Its clinical pipeline includes filgotinib, GLP3667, Toledo program, and idiopathic pulmonary fibrosis. The company was founded by Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es on June 30, 1999 and is headquartered in Mechelen, Belgium.

Clinical Trials

A Study to Test Safety, Tolerability, and the Way the Body Absorbs, Distributes, and Gets Rid of a Study Drug Called MOR106, in Healthy Subjects and in Patients With Moderate to Severe Atopic Dermatitis

Phase 1

Terminated

Conditions: Healthy
Atopic Dermatitis

Interventions: Drug: MOR106
Drug: Placebo

First Posted Date: 2018-09-28

Last Posted Date: 2020-03-18

Lead Sponsor: Galapagos NV

Target Recruit Count: 44

Registration Number: NCT03689829

Locations: 🇪🇸
Hospital Ramon y Cajal, Madrid, Spain
🇪🇸
Hospital General Universitario de Valencia, Valencia, Spain
🇩🇪
Municipal Hospital Dessau, Dessau, Germany

and more 12 locations

A Study to Assess Efficacy and Safety of GLPG1972/S201086 in Participants With Knee Osteoarthritis

Phase 2

Completed

Conditions: Osteoarthritis

Interventions: Drug: GLPG1972
Drug: Placebo

First Posted Date: 2018-07-23

Last Posted Date: 2021-07-28

Lead Sponsor: Galapagos NV

Target Recruit Count: 932

Registration Number: NCT03595618

Locations: 🇺🇸
The Helm Center for Pain Management, Laguna Hills, California, United States
🇺🇸
Pioneer Research Solutions Inc., Houston, Texas, United States
🇺🇸
Northwestern University, Chicago, Illinois, United States

and more 41 locations

Pharmacokinetics of GLPG3067 in Male Subjects With Cystic Fibrosis.

Phase 1

Completed

Conditions: Cystic Fibrosis

Interventions: Drug: GLPG3067 single dose

First Posted Date: 2018-07-17

Last Posted Date: 2018-07-17

Lead Sponsor: Galapagos NV

Target Recruit Count: 6

Registration Number: NCT03589313

Locations: 🇧🇪
University Hospital Leuven,Pediatric Pulmonology, Leuven, Belgium

A Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics (PK)/Pharmacodynamics (PD) of MOR106 in Subjects With Moderate to Severe Atopic Dermatitis

Phase 2

Terminated

Conditions: Atopic Dermatitis

Interventions: Drug: MOR 106
Drug: Placebo

First Posted Date: 2018-06-26

Last Posted Date: 2020-03-18

Lead Sponsor: Galapagos NV

Target Recruit Count: 207

Registration Number: NCT03568071

Locations: 🇩🇪
Fachklinik Bad Bentheim, Department of Dermatology, Bad Bentheim, Germany
🇬🇧
Whipps Cross Hospital, Leytonstone, United Kingdom
🇵🇱
4HEALTH, Wrocław, Poland

and more 49 locations

A Study Looking at the Safety, Tolerability and Efficacy of the Combination of the Study Drugs GLPG2451 and GLPG2222 With or Without GLPG2737 in Patients With Cystic Fibrosis.

Phase 1

Completed

Conditions: Cystic Fibrosis

Interventions: Drug: GLPG2451 dose regimen A
Drug: GLPG2451 dose regimen B
Drug: GLPG2222
Drug: GLPG2737

First Posted Date: 2018-05-30

Last Posted Date: 2019-04-08

Lead Sponsor: Galapagos NV

Target Recruit Count: 10

Registration Number: NCT03540524

Locations: 🇳🇱
Study Site NLD002, Amsterdam, Netherlands
🇳🇱
Study Site NLD001, Utrecht, Netherlands
🇧🇬
Study Site BGR001, Sofia, Bulgaria

and more 17 locations

A Study in Healthy Male Volunteers to Look at How the Test Medicine GLPG1690 is Taken up by the Body When Doses of Itraconazole and Voriconazole Are Given to Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: GLPG1690
Drug: Itraconazole
Drug: Voriconazole

First Posted Date: 2018-05-03

Last Posted Date: 2018-06-11

Lead Sponsor: Galapagos NV

Target Recruit Count: 18

Registration Number: NCT03515382

Locations: 🇬🇧
Quotient Sciences Limited, Ruddington, United Kingdom

GLPG2737 on Top of Orkambi in Subjects With Cystic Fibrosis

Phase 2

Completed

Conditions: Cystic Fibrosis

Interventions: Drug: Placebo
Drug: GLPG2737

First Posted Date: 2018-03-22

Last Posted Date: 2018-06-11

Lead Sponsor: Galapagos NV

Target Recruit Count: 22

Registration Number: NCT03474042

Locations: 🇩🇪
Study Site II, Berlin, Germany
🇩🇪
Study Site X, Dresden, Germany
🇩🇪
Study Site III, Essen, Germany

and more 6 locations

Pharmacokinetics of GLPG2737 in Male Subjects With Cystic Fibrosis

Phase 1

Completed

Conditions: Cystic Fibrosis

Interventions: Drug: GLPG2737 single dose

First Posted Date: 2018-03-01

Last Posted Date: 2018-03-19

Lead Sponsor: Galapagos NV

Target Recruit Count: 6

Registration Number: NCT03450720

Locations: 🇧🇪
UZ KU Leuven, Leuven, Belgium

A Study to Assess Safety, Tolerability and Pharmacokinetics of GLPG2737 in Healthy Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: GLPG2737 single dose
Drug: Placebo single dose
Drug: GLPG2737 multiple dose

First Posted Date: 2018-01-25

Last Posted Date: 2018-01-25

Lead Sponsor: Galapagos NV

Target Recruit Count: 79

Registration Number: NCT03410979

Locations: 🇳🇱
PRA-EDS, Groningen, Netherlands

An Open-label, Long-term Extension Study With Filgotinib in Active Psoriatic Arthritis.

Phase 2

Terminated

Conditions: Psoriatic Arthritis

Interventions: Drug: filgotinib

First Posted Date: 2017-10-25

Last Posted Date: 2022-04-21

Lead Sponsor: Galapagos NV

Target Recruit Count: 122

Registration Number: NCT03320876

Locations: 🇧🇬
UMHAT "Kaspela", EOOD, Plovdiv, Bulgaria
🇧🇪
ULB Hopital Erasme, Service de Rheumatology, Brussels, Belgium
🇧🇬
UMHAT "SofiaMed", OOD, Block 1, Sofia, Bulgaria

and more 22 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy